Oncotelic CEO Trieu buys 1.04M shares on October 29

The purchases were reported as open-market transactions made in Dr. Vuong Trieu's individual capacity, without a Rule 10b5-1 plan.

Accepted by SEC EDGAR 10/30/2026 - 09:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Oncotelic Therapeutics, Inc. (OTLC) Chairman and CEO Dr. Vuong Trieu purchased 312,000 common shares on October 28, 2026, at $0.0185 per share, and 1,044,990 shares on October 29, 2026, at $0.017 per share. Both purchases were from the open market and made in his individual capacity; no Rule 10b5-1 plan is reported.

Separately, reported indirect holdings as of October 28, 2026 include 16,780,384 shares by Autotelic Inc. and 6,872,529 shares by his spouse.

Insider Trade Summary

Net Buyer: 1,356,990 shares

Net Buy 2 txns

Insider Trieu Vuong

Role CHAIRMAN AND CEO

Bought 1,356,990 shs ($24K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	1,044,990	$0.017	$18K
Purchase	Common Stock F2	312,000	$0.0185	$6K
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 95,481,309 shares (Direct); Common Stock — 16,780,384 shares (Indirect, By Autotelic Inc.); Common Stock — 6,872,529 shares (Indirect, By spouse)

Footnotes (2)

1. F1. On October 29, 2026, Dr. Vuong Trieu purchased 1,044,990 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.017.
2. F2. On October 28, 2026, Dr. Vuong Trieu purchased 312,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0185.

Key Figures

Common shares purchased: 312,000 shares Price per share: $0.0185 per share Common shares purchased: 1,044,990 shares +3 more

6 metrics

Common shares purchased 312,000 shares October 28, 2026; individual capacity

Price per share $0.0185 per share Purchase on October 28, 2026

Common shares purchased 1,044,990 shares October 29, 2026; individual capacity

Price per share $0.017 per share Purchase on October 29, 2026

Indirect shares held by Autotelic Inc. 16,780,384 shares Holding dated October 28, 2026

Indirect shares held by spouse 6,872,529 shares Holding dated October 28, 2026

Key Terms

Rule 10b5-1 plan, individual capacity, indirect ownership

3 terms

Rule 10b5-1 plan regulatory

"no Rule 10b5-1 plan is reported"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

individual capacity technical

"purchased ... in his individual capacity"

indirect ownership financial

"By Autotelic Inc.; By spouse"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many OTLC shares did Vuong Trieu purchase, and at what prices?

Dr. Vuong Trieu purchased 312,000 shares on October 28, 2026, at $0.0185 per share and 1,044,990 shares on October 29, 2026, at $0.017 per share. Both purchases were from the open market, made in his individual capacity, and reported without a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trieu Vuong

(Last) (First) (Middle)

29397 AGOURA RD SUITE 107

(Street)

AGOURA HILLS CALIFORNIA 91301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncotelic Therapeutics, Inc. [ OTLC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CHAIRMAN AND CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/29/2026(1)	10/29/2026(1)	P		1,044,990	A	$0.017	95,481,309	D
Common Stock	10/28/2026(2)	10/28/2026(2)	P		312,000	A	$0.0185	94,436,319	D
Common Stock								16,780,384	I	By Autotelic Inc.
Common Stock								6,872,529	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On October 29, 2026, Dr. Vuong Trieu purchased 1,044,990 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.017.

2. On October 28, 2026, Dr. Vuong Trieu purchased 312,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0185.

	/s/ Vuong Trieu	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)